Last reviewed · How we verify
NCT07164079: RCT
Rubus Sanctus (Wild Blackberry) Root Extract as a Dietary Supplement for Graves' Disease
NA trial testing blackberry root in Graves Disease (Basedow's Disease) in 42 participants. Currently enrolling.
31 March 2026
Quick facts
| Lead sponsor | Betul Uner |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 42 |
| Start date | 12 December 2024 |
| Primary completion | 31 March 2026 |
| Estimated completion | 30 June 2026 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- blackberry root
- black tea — full drug profile →
Conditions studied
- Graves Disease (Basedow's Disease) — all drugs for Graves Disease (Basedow's Disease) →
Sponsor
Betul Uner
Who can join
Adults 18 to 65, any sex, with Graves Disease (Basedow's Disease). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this single-blind, randomized, experimental study was to investigate the effect of Rubus sanctus root extract, which has antioxidant properties, added to the routine diet of patients with Graves' disease on the prognosis of the disease. The study sample included patients who presented to the Endocrinology and Metabolic Diseases Outpatient Clinic of Muğla Sıtkı Koçman University Training and Research Hospital and were diagnosed with Graves' disease or developed a relapse after necessary examinations. Cohen's standardized effect size was used. Accordingly, the required sample size for the study was determined to be 42, using an alpha value of 0.05, an effect size of 0.80, and a theoretical power of 80%. The study planned to include a minimum of 42 participants: 21 intervention participants and 21 controls. Patients assigned to the control group were asked to continue their routine diet, adhere to any necessary pharmacological treatments, and consume a placebo tea for the planned 8-week intervention period. Routine monthly examinations will be collected, and anthropometric measurements will be repeated at the end of 8 weeks. Patients assigned to the experimental group will be asked to continue their routine diet for 8 weeks, comply with any required pharmacological treatments, and consume Rubus sanctus root extract, produced by aqueous extraction and lyophilization, with active ingredient (phenolic compound) determined by LC-MS-MS, and prepared as a tea in 5-g packets. Anthropometric measurements will be repeated at the end of 8 weeks. H0: Rubus sanctus root extract supplemented to the diet has no effect on Graves' disease. H1: Rubus sanctus root extract supplemented to the diet has an effect on Graves' disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07164079
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Betul Uner trials
Trials by the same sponsor.
- NCT07057999 — Investigation of the Effect of the MIND Diet on Disease Symptoms in Patients With MS · NA · completed
- NCT07054762 — Effects of Omega-3 Supplementation on Exercise Performance, Body Composition, and Appetite Status in Female Athletes · NA · completed
- NCT07090993 — Behavior Development Training for Sustainable Nutrition · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07164079 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Betul Uner
- Last refreshed: 9 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07164079.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing